• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Targeted survival improvements in clinical trials: are you an absolutist or relativist?临床试验中针对性的生存改善：你是绝对主义者还是相对主义者？
Cancer. 2015 Feb 1;121(3):335-8. doi: 10.1002/cncr.29031. Epub 2014 Oct 2.
2
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.预期性评估：上皮性卵巢癌随机3期研究中标准治疗结果的预测准确性
Cancer. 2015 Feb 1;121(3):413-22. doi: 10.1002/cncr.29030. Epub 2014 Oct 2.
3
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients.脱发作为原发性上皮性卵巢癌患者化疗反应的替代标志物：对四项涉及5114例患者的前瞻性随机III期试验的荟萃分析。
Eur J Cancer. 2015 May;51(7):825-32. doi: 10.1016/j.ejca.2015.01.008. Epub 2015 Mar 11.
4
The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.盲法独立影像学审查在卵巢癌临床试验中的作用：识别其价值。
Gynecol Oncol. 2021 May;161(2):491-495. doi: 10.1016/j.ygyno.2021.02.031. Epub 2021 Mar 13.
5
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.抗血管生成治疗在晚期卵巢癌治疗中的应用——机制、III 期随机临床试验综述及监管影响。
Gynecol Oncol. 2014 Feb;132(2):496-505. doi: 10.1016/j.ygyno.2013.11.029. Epub 2013 Dec 3.
6
Reporting and exclusion of sexual and gender minorities in cancer clinical trials.癌症临床试验中性少数群体和性别少数群体的报告与排除
Int J Cancer. 2020 Apr 15;146(8):2360-2361. doi: 10.1002/ijc.32700. Epub 2019 Nov 1.
7
Olaparib for the treatment of epithelial ovarian cancer.奥拉帕利用于治疗上皮性卵巢癌。
Expert Opin Pharmacother. 2016;17(7):995-1003. doi: 10.1517/14656566.2016.1165205. Epub 2016 Apr 4.
8
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.抗血管生成药物应当被整合到卵巢癌患者的标准治疗方案中。
Ann Oncol. 2011 Dec;22 Suppl 8:viii65-viii68. doi: 10.1093/annonc/mdr529.
9
[IV. Targeted therapies for epithelial ovarian cancer].
Gan To Kagaku Ryoho. 2014 Feb;41(2):193-8.
10
Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.抗血管生成疗法与剂量密集型紫杉醇疗法用于上皮性卵巢癌一线治疗的比较：III期随机临床试验综述
Curr Oncol Rep. 2014 Nov;16(11):412. doi: 10.1007/s11912-014-0412-2.

引用本文的文献

1
Choosing the target difference ('effect size') for a randomised controlled trial - DELTA guidance protocol.为随机对照试验选择目标差异（“效应量”）——DELTA指南方案。
Trials. 2017 Jun 12;18(1):271. doi: 10.1186/s13063-017-1969-5.
2
Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha - can tumor immune escape after immunotherapy accelerate disease progression?使用多亚型干扰素-α的免疫疗法在黑色素瘤中的相反作用——免疫疗法后的肿瘤免疫逃逸会加速疾病进展吗？
Oncoimmunology. 2015 Oct 29;5(3):e1091147. doi: 10.1080/2162402X.2015.1091147. eCollection 2016 Mar.

本文引用的文献

1
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.预期性评估：上皮性卵巢癌随机3期研究中标准治疗结果的预测准确性
Cancer. 2015 Feb 1;121(3):413-22. doi: 10.1002/cncr.29030. Epub 2014 Oct 2.
2
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.超越风险比：在生存分析中量化组间差异。
J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.
3
Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.评估指定随机对照试验目标差值的方法：DELTA（试验中差值确定）综述。
Health Technol Assess. 2014 May;18(28):v-vi, 1-175. doi: 10.3310/hta18280.
4
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.美国临床肿瘤学会观点：通过定义具有临床意义的结果来提高临床试验标准。
J Clin Oncol. 2014 Apr 20;32(12):1277-80. doi: 10.1200/JCO.2013.53.8009. Epub 2014 Mar 17.
5
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.限制平均生存时间：替代风险比的方法，用于设计和分析具有时间事件结局的随机试验。
BMC Med Res Methodol. 2013 Dec 7;13:152. doi: 10.1186/1471-2288-13-152.
6
Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications.癌症免疫疗法试验中生存曲线的晚期离散：解释与意义。
Cancer Immunol Immunother. 2013 Oct;62(10):1547-51. doi: 10.1007/s00262-013-1458-y. Epub 2013 Aug 24.
7
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.贝伐珠单抗在 II-III 期结肠癌中的应用：国家外科辅助乳腺和肠道项目 C-08 试验的 5 年更新。
J Clin Oncol. 2013 Jan 20;31(3):359-64. doi: 10.1200/JCO.2012.44.4711. Epub 2012 Dec 10.
8
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.随机 III 期临床试验中评估癌症系统治疗预期获益的假设。
J Natl Cancer Inst. 2012 Apr 18;104(8):590-8. doi: 10.1093/jnci/djs141. Epub 2012 Apr 6.
9
Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?总生存期：患者预后、治疗目标、临床试验终点还是公共卫生指标？
J Clin Oncol. 2012 May 20;30(15):1750-4. doi: 10.1200/JCO.2011.38.6359. Epub 2012 Mar 5.
10
Progression-free survival: meaningful or simply measurable?无进展生存期：有意义还是仅仅可测量？
J Clin Oncol. 2012 Apr 1;30(10):1030-3. doi: 10.1200/JCO.2011.38.7571. Epub 2012 Feb 27.

Targeted survival improvements in clinical trials: are you an absolutist or relativist?

作者信息

Paul James

机构信息

Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

出版信息

Cancer. 2015 Feb 1;121(3):335-8. doi: 10.1002/cncr.29031. Epub 2014 Oct 2.

DOI:10.1002/cncr.29031
PMID:25278175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4328455/
Abstract
摘要